The effect of pharmacological doses of different antioxidants on oxidation parameters and atherogenesis in hyperlipidaemic rabbits.
The oxidation hypothesis of atherosclerosis implies that antioxidants are able to inhibit lipoprotein oxidation in the arterial wall and thereby retard atherogenesis. Since most of the animal studies performed have used very high doses of antioxidants, it is to date unknown whether antioxidants are effective antiatherosclerotic agents when given in pharmacological doses. Here we addressed this question using homozygous Watanabe heritable hyperlipidaemic (WHHL) rabbits as an animal model of atherosclerosis. The rabbits were divided into four groups, each consisting of ten animals. They received either a standard diet or a diet containing 4.3 mg ubiquinone-10, or 4.3 mg vitamin E or 15 mg probucol/kg body weight daily. After 12 months, the extent of aortic atherosclerosis was assessed as the intima thickness, media thickness and intima-to-media ratio in 14 cross sections equally distributed over the whole aorta. To evaluate the antioxidant effects of the diet, lipophilic and hydrophilic antioxidants, lipids, fatty acids and plasma oxidizability were measured after 0, 3 and 6 months of feeding. We found that supplementation with probucol significantly decreased aortic intima-to-media ratio compared to controls. The antiatherosclerotic action of probucol was accompanied by its beneficial action on plasma oxidizability and some plasma antioxidants. No decrease in aortic atherosclerosis was measured in ubiquinone-10- and vitamin E-supplemented rabbits, despite the fact that both antioxidants decreased plasma oxidizability and ubiquinone-10 increased the plasma levels of antioxidants. Taken together, these data suggest that pharmacological doses of probucol retard atherogenesis in WHHL rabbits by an antioxidant mechanism, while ubiquinone-10 and vitamin E at these dosages are ineffective in this highly hyperlipidaemic model. The measurement of some oxidation-related parameters in plasma, such as lipophilic antioxidants, polyunsaturated fatty acids and lipoprotein oxidizability, may be useful in assessing the risk of atherogenesis in humans.
Djahansouzi
S
S
Biochemisches Labor, Pav. 39, Medizinische Kern- und Poliklinik, Universitätskrankenhaus Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Braesen
J H
JH
Koenig
K
K
Beisiegel
U
U
Kontush
A
A
D000284:Administration, Oral; D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D000931:Antidotes / Q000008:administration & dosage / Q000493:pharmacokinetics; D000975:Antioxidants / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001011:Aorta / Q000187:drug effects / Q000473:pathology; D001161:Arteriosclerosis / Q000097:blood / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D004032:Diet; D004305:Dose-Response Relationship, Drug; D005231:Fatty Acids, Unsaturated / Q000097:blood; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000628:therapy*; D008074:Lipoproteins / Q000097:blood; D010084:Oxidation-Reduction / Q000187:drug effects*; D011341:Probucol / Q000008:administration & dosage / Q000493:pharmacokinetics; D011817:Rabbits; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology; D014451:Ubiquinone / Q000008:administration & dosage / Q000493:pharmacokinetics; D014810:Vitamin E / Q000008:administration & dosage / Q000493:pharmacokinetics
D000924:Anticholesteremic Agents; D000931:Antidotes; D000975:Antioxidants; D005231:Fatty Acids, Unsaturated; D008074:Lipoproteins; D014451:Ubiquinone; D014810:Vitamin E; C025204:Ubiquinone Q2; D011341:Probucol